Core Viewpoint - An amended securities class action lawsuit has been filed against CarMax, Inc., expanding the class period to include those who purchased CarMax securities between June 20, 2025, and November 5, 2025 [1] Group 1: Allegations Against CarMax - The complaint alleges that Defendants made false and/or misleading statements regarding CarMax's growth prospects, claiming that earlier growth was a temporary benefit due to customer speculation about tariffs [3] - It is asserted that the positive statements made by Defendants about the company's business and operations were materially misleading and lacked a reasonable basis [3] Group 2: Legal Process and Participation - CarMax investors can seek to be appointed as a lead plaintiff representative of the class by January 2, 2026, or may choose to remain absent [4] - The lead plaintiff will act on behalf of all class members and select counsel to represent the class, with the ability to share in any recovery not affected by the decision to serve as a lead plaintiff [4] Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is encouraging CarMax investors who have suffered significant losses to contact the firm for more information [5] - The firm has a global reputation for excellence in prosecuting class actions and has recovered billions for victims of fraud and corporate misconduct [5]

Core Viewpoint - Securities class action lawsuits have been filed against DexCom, Inc. for alleged misleading statements and undisclosed material changes to its glucose monitoring systems during the specified class period [1][2]. Allegations Against DexCom - Defendants allegedly made false and misleading statements regarding unauthorized design changes to the G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [2]. - The enhancements claimed for the G7 device were reportedly overstated, and the company downplayed the severity of issues related to the adulterated devices [2]. - These actions have led to increased regulatory scrutiny and potential legal, reputational, and financial harm for DexCom [2]. Lead Plaintiff Process - Investors in DexCom have until December 26, 2025, to seek appointment as lead plaintiff representatives in the class action, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or group of investors with the largest financial interest in the case [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [5].